[Behavior of lactate and pyruvate in diabetics during ambulatory treatment with biguanides or with a combination of biguanides and sulfonylureas. II].
D000368:Aged; D000553:Ambulatory Care; D001645:Biguanides / Q000008:administration & dosage* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000209:etiology / Q000517:prevention & control; D004338:Drug Combinations; D005260:Female; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007773:Lactates / Q000378:metabolism*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use; D011773:Pyruvates / Q000378:metabolism*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000627:therapeutic use
D001645:Biguanides; D004338:Drug Combinations; D007773:Lactates; D011773:Pyruvates; D013453:Sulfonylurea Compounds; D008687:Metformin; D010629:Phenformin; D005905:Glyburide
Comportamento del lattato e piruvato in diabetici in trattamento ambulatoriale con biguanidi o con associazione biguanidi-sulfoniluree. Nota II.